Colin Walsh

Colin Walsh, PhD, currently serves as Managing Director of Life Sciences Investing at Goldman Sachs since September 2023 and holds a board member position at Attovia Therapeutics. Prior experience includes serving as a Partner at Qiming Venture Partners USA from April 2019 to October 2023 and as a board member for multiple companies including Abdera Therapeutics, Entact Bio, Element Science, and Korro Bio, among others, throughout 2021 to 2023. Colin Walsh has also held roles as a board observer for Ventyx Biosciences and Icosavax, Inc. Educationally, Colin Walsh earned a PhD in Bioengineering from both the University of California, San Francisco and the University of California, Berkeley, along with a Certificate in Management of Technology from the Haas School of Business at UC Berkeley, and a B.S. in Chemical Engineering and Biochemistry from the University of Massachusetts Amherst.